CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions.
Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
全球癌症死亡的主要原因归因于非小细胞肺癌(NSCLC),因此需要持续关注改善该疾病的诊断和治疗。在本综述中,重点介绍了NSCLC管理方面的最新突破和新兴趋势。讨论了诊断方法的重大进展,包括更好的影像技术和分子生物标志物的利用。这些进展极大地增强了早期检测和个性化治疗方案。新的靶向治疗和免疫治疗已显著改善患者结局,为晚期NSCLC个体带来了新的希望。本综述讨论了尽管近期取得进展,但在获得先进治疗及其相关费用方面仍持续存在的挑战。还重点介绍了对CAR-T 细胞治疗和溶瘤病毒等新疗法的有前景的研究,这些疗法可能进一步革新NSCLC治疗。本综述旨在通过全面概述NSCLC治疗的当前状况和未来可能性,为全球改善NSCLC患者结局的持续努力提供信息并激发灵感。
The leading cause of cancer deaths worldwide is attributed to non-small cell lung cancer (NSCLC), necessitating a continual focus on improving the diagnosis and treatment of this disease. In this review, the latest breakthroughs and emerging trends in managing NSCLC are highlighted. Major advancements in diagnostic methods, including better imaging technologies and the utilization of molecular biomarkers, are discussed. These advancements have greatly enhanced early detection and personalized treatment plans.
Significant improvements in patient outcomes have been achieved by new targeted therapies and immunotherapies, providing new hope for individuals with advanced NSCLC. This review discusses the persistent challenges in accessing advanced treatments and their associated costs despite recent progress.
Promising research into new therapies, such as CAR-T cell therapy and oncolytic viruses, which could further revolutionize NSCLC treatment, is also highlighted. This review aims to inform and inspire continued efforts to improve outcomes for NSCLC patients globally, by offering a comprehensive overview of the current state of NSCLC treatment and future possibilities.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。